The GLP-1 Research Landscape in 2026: From Semaglutide to Next-Generation Agonists

The GLP-1 receptor was the first target because GLP-1 itself is an endogenous incretin hormone with an established pharmacology going back decades. Semaglutide is essentially an optimised, long-acting version of the native GLP-1 molecule — same mechanism, extended half-life through fatty acid conjugation and amino acid substitutions that prevent DPP-4 degradation.

The non-obvious finding in the dual and triple agonism data is that the effects of each additional receptor are roughly additive rather than redundant. You might expect that there's only so much appetite you can suppress, so adding more receptors would produce diminishing returns past a certain point. The clinical data suggests that isn't quite right — at least not yet.

The reason may be that the different receptor targets are addressing different aspects of energy balance rather than the same mechanism through different pathways. GLP-1 agonism primarily reduces caloric intake. GIP agonism improves how efficiently the body handles the calories that are consumed (insulin sensitivity, adipose lipid metabolism). Glucagon receptor agonism increases how many calories the body burns at baseline (thermogenesis). These are genuinely distinct physiological processes — which is why combining them produces compound effects.

Beyond adding receptor targets, the field is also exploring biased agonism — the idea that different ligands at the same receptor can selectively activate distinct downstream signalling pathways. At the GLP-1 receptor, the two main pathways are cAMP/PKA signalling (driving insulin secretion and the metabolic effects) and β-arrestin recruitment (driving receptor internalisation and potentially distinct cardioprotective effects).

Compounds with different structural features can preferentially engage one pathway over the other — this is called "functional selectivity" or biased agonism. Research peptides allow systematic study of which structural modifications drive cAMP versus β-arrestin bias, with potential implications for designing compounds with optimised therapeutic indices. This is an active area of basic research that goes well beyond the current clinical development focus on weight loss.

Small molecule GLP-1 agonists are also a significant frontier. Oral peptide bioavailability remains challenging — semaglutide oral tablets use an absorption enhancer (SNAC) and have ~1% bioavailability. Compounds like orforglipron and danuglipron achieve GLP-1 agonism via non-peptide molecular scaffolds with conventional oral bioavailability, potentially removing the need for injections. These are entering Phase 3 now, and their data will be important for understanding how much of the GLP-1 class's effect is receptor-driven versus route-of-administration-specific.

The GLP-1 class commands most of the metabolic research attention right now, but adjacent hormone axes are also relevant to researchers studying visceral fat, insulin resistance, and metabolic syndrome. Tesamorelin — the FDA-approved GHRH analogue — demonstrated specific visceral adipose tissue reduction in HIV-associated lipodystrophy through a growth hormone-mediated mechanism. This positions it as a complementary tool for researchers studying visceral fat mobilisation through a GH/IGF-1 pathway distinct from the GLP-1/GIP/glucagon system.

Understanding the intersection of the GH axis and GLP-1 axis in metabolic regulation is an open research question — particularly in the context of age-related visceral adiposity, where both GH secretion and incretin sensitivity decline simultaneously.